Navigation Links
Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer
Date:2/1/2011

eveloping biomedical countermeasures pursuant to the Project BioShield Act of 2004. Soligenix's lead biodefense product in development is a recombinant subunit vaccine called RiVax™, which is designed to protect against the lethal effects of exposure to ricin toxin. RiVax™ has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers. RiVax™ is also the subject of a $9.4 million NIAID grant received by the Company supporting development of new heat stable vaccines.

For further information regarding Soligenix, Inc., please visit the Company's website at www.soligenix.com.

This press release contains forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec®, SGX201, RiVax™, and LPM™, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
9. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
10. Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
11. Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015  Profil Institute for ... on diabetes and obesity, announced today a new textbook,  ... Development,  published by Springer, a leading global scientific publisher. ... analyze and illustrate techniques for use in early phase ...
(Date:1/22/2015)... Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has announced the addition ... & by End User - Global Forecast to 2019" ... diagnostics market is valued at $1,228.58 million in 2014 and ... reach $2,230.72 million by 2019. Allergy diagnostics is used to ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... Oct. 15 /PRNewswire-FirstCall/,-- Lexicon Pharmaceuticals, Inc. (Nasdaq: ... clinical trial results for LX1031 at the ... in Philadelphia, Pennsylvania. The,studies demonstrated that LX1031 ... that exposure levels in blood were low. ...
... control in patients with type ... has been accepted for publication, OWINGS MILLS, Md., Oct. ... a study conducted by researchers at the,Johns Hopkins University Bloomberg ... peer-reviewed journal which is scheduled for,release in an early 2008 ...
Cached Medicine Technology:Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome 2Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome 3Medifast, Inc. Announces Acceptance for Publication of Clinical Efficacy Study 2
(Date:1/23/2015)... 2015 Hastings and Hastings, a law firm ... record number of legal representation client review requests for slip ... a steady rise in the number of slip and fall ... throughout the Valley. With that said, a large number of ... an experienced law firm. Hastings and Hastings is a personal ...
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has been ... business is showing its latest designs of wedding dresses and ... the company’s CEO, all the fresh new products are designed ... up to 80% off. All the clothes from LunaDress follow ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in ... Player Health Alliance (PPHA). The PPHA's passion for others' ... including NFL greats, treated for obstructive sleep apnea (OSA) has ... the cause in the valley. The most recent plans for ...
(Date:1/22/2015)... Minn. (PRWEB) January 22, 2015 Blue Cross ... those Minnesotans who exemplify what it means to “Live Fearless.” ... chance for people to share their stories about how they ... or simply inspired others by living in the moment. By ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... , FRIDAY, Feb. 25 (HealthDay News) -- Infants ... for childhood obesity, but breast-feeding lowers that risk, a new ... those who were breast-fed for six months or more were ... were 6 to 13 years old than children whose mothers ...
... , FRIDAY, Feb. 25 (HealthDay News) -- Depression ... and 40s who are prone to addiction problems and ... at how personal history, family life and neighborhood instability ... period during their early years of marriage and motherhood. ...
... FRIDAY, Feb. 25 (HealthDay News) -- Most patients struggling ... called idiopathic pulmonary fibrosis do not risk ... exposure to a viral infection, new research indicates. ... viral infections might rapidly advance disease in patients diagnosed ...
... Reporter , THURSDAY, Feb. 24 (HealthDay News) -- Experts ... of impending dangers to human health if greenhouse gas ... the federal government, specifically the Environmental Protection Agency, ... "The science is unequivocal that global warming is ...
... drug that is currently used to help treat bone metastases ... an earlier stage of treatment, to prevent the cancer from ... Dr Michela Quirino and colleagues from the Catholic University of ... that zoledronic acid may be able to prevent lung cancer ...
... THURSDAY, Feb. 24 (HealthDay News) -- While experts stress that ... past, isolated cases still appear, even in the United States. ... American lab worker died from plague in 2009 -- the ... and the first known death from a weakened form of ...
Cached Medicine News:Health News:Breast-Feeding May Cut Obesity Risk in Kids of Diabetic Moms 2Health News:Depression May Worsen Over Time in Addiction-Prone Women 2Health News:Virus Unlikely to Advance Deadly Lung Disease: Study 2Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 2Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 3Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 4Health News:Bone drug zoledronic acid may help prevent spread of early lung cancer 2Health News:Plague Kills U.S. Lab Worker 2Health News:Plague Kills U.S. Lab Worker 3